NEW YORK -- Rafael Palmeiro's positive steroid test was for stanozolol, a powerful anabolic steroid that is not available in dietary supplements, according to a newspaper report.
The New York Times, citing a person in baseball with direct knowledge of the sport's drug-testing program, reported on its Web site Tuesday that Palmeiro tested positive for the drug known by the brand name Winstrol, most notably linked to the Olympic sprinter Ben Johnson of Canada.
The person who said that Palmeiro tested positive for stanozolol did not want to be identified because the testing policy prohibits anyone in baseball from disclosing information about test results without authorization, the Times said.
The Baltimore Orioles first baseman was suspended by Major League Baseball for 10 days on Monday after testing positive for a performance-enhancing drug. The highest profiled player to be punished so far, Palmeiro testified before Congress in March that he "never used steroids."
The test was taken some weeks after Palmeiro testified before Congress in March, meaning he is probably not at risk for perjury, the Times reported, citing a committee staff member who spoke to the newspaper on condition of anonymity because official statements are supposed to come from members of Congress.
Palmeiro didn't deny turning in a positive test, but was adamant it was an accident.
Johnson was stripped of his 100-meter gold medal in 1988 after testing positive for stanozolol.
Palmeiro was the seventh player to fall under baseball's new, tougher steroids policy; Seattle Mariners right-hander Ryan Franklin became the eighth when he was also suspended 10 days for a violation Tuesday. Baseball does not release what type of drug a player has tested positive for, and so far none of the eight have spoken openly about details of their violations.
Connect with the Southeast Missourian Newsroom:
For corrections to this story or other insights for the editor, click here. To submit a letter to the editor, click here. To learn about the Southeast Missourian’s AI Policy, click here.